Lasofoxifene(CAS: 180916-16-9)

Lasofoxifene (CAS: 180916-16-9) is subject to regulatory guidelines including the REACH regulations in the European Union, which require comprehensive safety data sheets (SDS) and registration for substances above one tonne per year. Additionally, it may be regulated by the EPA in the USA under the Toxic Substance Control Act (TSCA) and the FDA for pharmaceutical applications. Users should comply with local and international chemical safety and environmental regulations.

Several alternatives to Lasofoxifene (CAS: 180916-16-9) exist in synthesis, including related estrogen receptor modulators such as tamoxifen and raloxifene. These compounds can be used as analogs or starting materials in the development of new drugs or research. Common alternative reagents include various aromatic alcohols and amines that can be used in similar synthetic routes.

Lasofoxifene (CAS: 180916-16-9) is primarily used in pharmaceutical research for its estrogen receptor modulating properties. Market trends suggest increasing interest in compounds that can mimic or block estrogen activity without the side effects associated with traditional estrogen therapy. Research is focusing on its potential applications in osteoporosis, breast cancer, and menopausal symptoms. Price trends are influenced by demand and production costs, with a focus on cost-effectiveness in clinical trials.

Waste containing Lasofoxifene (CAS: 180916-16-9) should be collected in appropriate containers and stored in a secure location. It should be disposed of through a licensed hazardous waste disposal service to ensure compliance with environmental regulations. Incineration is a common method for disposing of such waste, but it must be conducted in a controlled environment to prevent the release of harmful substances. Environmental protection precautions include ensuring no leakage into soil or water during handling and disposal processes.